Global Typhoid Fever Vaccines Market: A Report on Market Dynamics and Contributions to Sustainable Development Goals

Introduction: Addressing a Global Health Challenge

Typhoid fever persists as a significant public health issue, intrinsically linked to inadequate infrastructure as outlined in SDG 6 (Clean Water and Sanitation). Vaccination serves as a critical intervention to control the disease, directly supporting SDG 3 (Good Health and Well-being) by reducing disease burden and mortality. The global market for typhoid fever vaccines is expanding, driven by government-led immunization programs and growing awareness. The market is projected to grow from an estimated USD 1.75 billion in 2025 to USD 3.5 billion by 2032, with a compound annual growth rate (CAGR) of 12.2%.

Alignment with Sustainable Development Goals (SDGs)

SDG 3: Good Health and Well-being

The expansion of the typhoid vaccine market is a direct contributor to achieving universal health coverage and combating communicable diseases.

• Target 3.3 (End Epidemics): Increased vaccine uptake, such as the 15% rise in South Asia during 2024, is fundamental to controlling typhoid outbreaks in endemic regions.
• Target 3.8 (Universal Health Coverage): The development and distribution of effective vaccines, including next-generation conjugate vaccines, enhance access to essential medicines for all.
• Combating Antimicrobial Resistance (AMR): The rising incidence of antibiotic-resistant Salmonella Typhi strains underscores the importance of vaccination as a preventative measure, reducing reliance on antimicrobial treatments.

SDG 10: Reduced Inequalities

Efforts within the market are focused on ensuring equitable access to vaccines, addressing health disparities between and within countries.

• Subsidized pricing models introduced in nations like India and Indonesia in 2025 have increased immunization coverage by 30%, making prevention more affordable for low-income populations.
• A 25% year-on-year increase in vaccine shipments to Africa in 2024 demonstrates a commitment to supplying regions with high disease burdens, thereby reducing global health inequalities.

SDG 17: Partnerships for the Goals

Strategic collaborations between public and private sectors are vital for market growth and achieving public health objectives.

• Bharat Biotech’s partnerships with government health ministries across Asia have accelerated immunization campaigns.
• Regional initiatives, such as the African Vaccine Acquisition Task Team (AVATT), facilitate bulk procurement, improving supply chain resilience and cost-effectiveness.
• Leading companies like GlaxoSmithKline Plc. and Sanofi SA are engaging in R&D and localized supply chain optimizations to enhance vaccine accessibility and efficacy globally.

Key Market Drivers and Trends

Primary Growth Drivers

1. Rising Antimicrobial Resistance: The increasing prevalence of multidrug-resistant Salmonella Typhi is a primary catalyst, compelling governments to prioritize vaccination.
2. Global Health Recommendations: The WHO’s recommendation to include typhoid conjugate vaccines in routine immunization schedules has significantly expanded the market.
3. Urbanization and Population Growth: Rapid urbanization in the Asia Pacific and African regions, which accounted for over 60% of new immunizations in 2024, is fueling demand.
4. Technological Advancements: The development of improved conjugate vaccines with longer-lasting immunity stimulates market revenue by reducing the need for frequent booster doses.

Emerging Market Trends

• Shift Towards Conjugate Vaccines: The market is experiencing a significant shift towards conjugate vaccines, with a 35% increase in adoption in 2024 due to their superior immunogenicity, especially in pediatric populations.
• Digital Health Integration: Digital platforms are increasingly being utilized to streamline vaccine distribution, monitor immunization coverage, and enhance overall market efficiency.
• Bulk Procurement Strategies: Regional initiatives are promoting bulk purchasing, which helps reduce costs and improve supply chain stability in high-demand areas.

Market Segmentation Analysis

By Vaccine Type

• Conjugate Vaccines: This segment presents the highest impact opportunity, with an anticipated CAGR exceeding 14% through 2032, driven by expanding approval for pediatric use.
• Live Attenuated Vaccines
• Polysaccharide Vaccines
• Others

By End User and Distribution Channel

• End Users: Government immunization programs represent the largest growth opportunity, followed by hospitals and clinics.
• Distribution Channels: Hospital pharmacies are emerging as key channels, particularly in urban centers, alongside retail and online pharmacies.

Regional Outlook and Opportunities

Asia Pacific

This region is a dominant force in the market, characterized by a large population base and rising healthcare expenditure. India alone accounted for 40% of the vaccine market revenue in 2024, indicating robust growth opportunities.

Africa

The continent is an emerging market, highlighted by a significant increase in vaccine imports and strategic procurement initiatives aimed at reducing typhoid incidence and expanding immunization coverage.

Competitive Landscape

Leading Companies

• GlaxoSmithKline Plc.
• Sanofi SA
• Bharat Biotech
• Bio-Med Pvt. Ltd.
• PT Bio Farma
• PaxVax, Inc.
• Shanghai Institute of Biological Products Co., Ltd.
• Prokarium

Strategic Initiatives

• GlaxoSmithKline Plc.: Invested USD 150 million in developing next-generation typhoid conjugate vaccines with enhanced efficacy.
• Bharat Biotech: Expanded production capacity, increasing global supply by 20% in 2024, and partnered with governments to boost immunization campaigns.
• Sanofi SA: Implemented dynamic pricing and localized supply chains in African markets, driving a 22% year-over-year revenue growth.

SDGs Addressed in the Article

SDG 3: Good Health and Well-being

• The article’s central theme is the Typhoid Fever Vaccines Market, which directly relates to preventing and treating communicable diseases. It discusses vaccination as a “critical intervention to control outbreaks and reduce disease burden globally,” which is a core objective of SDG 3. The text highlights efforts to combat typhoid fever, a significant public health challenge, through immunization programs, research and development (R&D), and ensuring vaccine accessibility.

SDG 6: Clean Water and Sanitation

• The article explicitly connects typhoid fever to environmental factors, stating it is a “significant public health challenge, particularly in regions with inadequate sanitation and limited access to clean water.” While the article focuses on a medical solution (vaccines), it acknowledges that the root cause of the disease is linked to the lack of basic services central to SDG 6.

SDG 9: Industry, Innovation, and Infrastructure

• The article details industrial and innovative efforts within the pharmaceutical sector. It mentions “Production capacity expansion by leading vaccine manufacturers,” “advancements in vaccine technology, such as improved conjugate vaccines,” and significant R&D investments, such as “GlaxoSmithKline Plc. invested USD 150 million in developing next-generation typhoid conjugate vaccines.” These points relate to upgrading technological capabilities and enhancing scientific research within the industry.

SDG 17: Partnerships for the Goals

• The article emphasizes the importance of collaboration to achieve public health goals. It provides examples such as “Bharat Biotech’s partnership with government health ministries across Asia” and regional initiatives like the “African Vaccine Acquisition Task Team (AVATT).” These multi-stakeholder partnerships between private companies, governments, and regional bodies are crucial for mobilizing resources and expertise to expand vaccine access, which is the essence of SDG 17.

Specific Targets Identified

SDG 3: Good Health and Well-being

1. Target 3.3: By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases.
   • The article directly addresses this target by focusing on typhoid fever, a water-borne communicable disease. The entire discussion on vaccines, immunization programs, and market growth is aimed at controlling and reducing the “disease burden globally.”
2. Target 3.8: Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all.
   • The article points to this target by discussing “government-led immunization programs,” “subsidized pricing models” in emerging markets, and strategies to increase “vaccine accessibility in African markets.” These efforts aim to make essential typhoid vaccines affordable and accessible to wider populations.
3. Target 3.b: Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries…
   • This target is supported by mentions of “aggressive R&D,” GlaxoSmithKline’s “$150 million” investment in developing new vaccines, and the overall focus on creating “improved conjugate vaccines with longer-lasting immunity” for a disease endemic in developing regions.

SDG 6: Clean Water and Sanitation

1. Target 6.2: By 2030, achieve access to adequate and equitable sanitation and hygiene for all…
   • The article implies the importance of this target by identifying “inadequate sanitation” as a primary reason for the prevalence of typhoid fever. While the article does not detail actions towards this target, it establishes the context that makes typhoid a persistent problem.

SDG 9: Industry, Innovation, and Infrastructure

1. Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries…
   • The article highlights this target through its discussion of “advancements in vaccine technology,” the “paradigm shift towards conjugate vaccines due to their superior immunogenicity,” and corporate R&D investments aimed at creating next-generation vaccines. It also mentions the “strategic scaling of Bharat Biotech’s production facilities,” which relates to upgrading industrial capabilities.

SDG 17: Partnerships for the Goals

1. Target 17.17: Encourage and promote effective public, public-private and civil society partnerships…
   • This target is clearly identified through examples of “Bharat Biotech’s partnership with government health ministries” and “strategic collaborations” among market players. The mention of the “African Vaccine Acquisition Task Team (AVATT)” also serves as a prime example of a multi-stakeholder partnership aimed at improving vaccine procurement and distribution.

Indicators for Measuring Progress

SDG 3: Good Health and Well-being

• Incidence of disease: The article mentions the “rising incidence of antibiotic-resistant strains of Salmonella Typhi” as a driver for vaccine demand, implying that disease incidence is a key metric.
• Vaccination coverage: The article provides specific quantitative indicators of progress. For example, a “15% increase in vaccine uptake in South Asia during 2024,” a “30% rise in immunization coverage” in India and Indonesia due to subsidized pricing, and the fact that Asia Pacific and Africa accounted for “over 60% of new immunizations in 2024.”
• Inclusion in routine immunization: The “WHO’s 2024 recommendation to include typhoid conjugate vaccines in routine immunization schedules for children under 15 years” serves as a policy-level indicator of progress towards universal access.

SDG 9: Industry, Innovation, and Infrastructure

• Investment in R&D: The article provides a specific financial figure: “GlaxoSmithKline Plc. invested USD 150 million in developing next-generation typhoid conjugate vaccines,” which can be used as an indicator of private sector R&D spending.
• Production capacity: The mention of Bharat Biotech’s expansion increasing “global supply by 20%” is a direct indicator of industrial capacity growth.
• Adoption of new technology: The “35% increase in conjugate vaccine adoption compared to traditional polysaccharide vaccines” is a clear indicator of the market shift towards more advanced technologies.

SDG 17: Partnerships for the Goals

• Existence and impact of partnerships: The article implies the success of partnerships through market outcomes, such as Bharat Biotech’s collaboration with governments boosting its “market share by 18% in 2025.” The formation of bodies like the “African Vaccine Acquisition Task Team (AVATT)” is itself a qualitative indicator of partnership-building.

Summary Table of SDGs, Targets, and Indicators

Source: openpr.com